Sexual impairment is common among men with chronic hepatitis C undergoing antiviral therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

This is the first time a study evaluating the combination therapy, peginterferon and ribavirin, has identified sexual dysfunction as a side effect. Sexual dysfunction and impairment of desire should be considered common side effects of combination antiviral therapy in men with hepatitis C. It has the potential to affect all three components of sexual health: desire, function and satisfaction.

Before therapy, 37 percent of men reported at least some degree of impairment in sexual desire, while 44 percent reported dissatisfaction with their sexual life. In addition, 22 percent reported impairment in erectile and 26 percent in ejaculatory function. The average onset of sexual dysfunction appeared to be within four weeks of starting antiviral therapy, and many patients reported a gradual worsening over time. At the end of therapy (24 or 48 weeks), an estimated 38 percent to 48 percent of men reported that overall sexual function was worse than before treatment. African Americans reported less impairment in sexual desire and satisfaction than Caucasian Americans during therapy. While most components of sexual health evaluated in this study resolved within six months after the cessation of therapy, erectile and ejaculatory function remained slightly worse than before therapy in a proportion of men who received a full 48 weeks of treatment.

As part of the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (VIRAHEP-C), 260 men treated with peginterferon alfa-2a and ribavirin completed self-administered questionnaires concerning sexual desire, sexual function — including erectile and ejaculatory function — and sexual satisfaction before, during and after treatment.

Chronic hepatitis C affects 1 percent to 2 percent of the American population and is more common among African Americans than Caucasian Americans and other racial and ethnic groups in the U.S. While current therapies for hepatitis C are evolving, at present they remain only partially effective.

Though sexual function and health are important elements of quality of life and overall well-being, they are infrequently mentioned in the discussion of complications of therapy with peginterferon and ribavirin. In fact, most review articles on hepatitis C treatment, summary publications on the side effects of therapy and the package inserts for peginterferon do not mention sexual dysfunction as a potential complication of therapy.

###

For more information on viral hepatitis, visit the AGA patient center at http://www.gastro.org/patient.

About the AGA Institute
The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to include 17,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. http://www.gastro.org.

About Gastroenterology
Gastroenterology, the official journal of the AGA Institute, is the most prominent scientific journal in the specialty and is in the top 1 percent of indexed medical journals internationally. The journal publishes clinical and basic science studies of all aspects of the digestive system, including the liver and pancreas, as well as nutrition. The journal is abstracted and indexed in Biological Abstracts, CABS, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Nutrition Abstracts and Science Citation Index. For more information, visit http://www.gastrojournal.org.

Contact: Alissa J. Cruz
.(JavaScript must be enabled to view this email address)
301-272-1603
American Gastroenterological Association